Screening Indications and Treatments for Cholangiocarcinoma
Current Hepatology Reports, ISSN: 2195-9595, Vol: 18, Issue: 4, Page: 408-416
2019
- 1Citations
- 2Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Purpose of Review: The goal of this review paper is to provide a comprehensive overview of cholangiocarcinoma (CCA) including its classification, epidemiology, risk factors, surveillance, diagnosis, and treatment. Recent Findings: Guidelines recommend CCA surveillance in PSC patients with MRI/MRCP or ultrasound and CA 19-9 every 6–12 months. Fluorescience in situ hybridization and next-generation sequencing improve the poor sensitivity of biliary brushings. Surgical resection with negative margins gives the best chance of survival, and liver transplantation is an option for patients with very early intrahepatic CCA and perihilar CCA. Summary: CCA is a deadly epithelial malignancy of the biliary-ductal system and is the second most common primary liver cancer. Surveillance should be offered to all patients with PSC. CCA carries poor prognosis, especially if resection or liver transplantion is not feasible. Novel biomarkers and therapeutic options such as molecularly targeted therapy and immunotherapy hold promise to improve the detection and outcome of CCA patients.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85159071810&origin=inward; http://dx.doi.org/10.1007/s11901-019-00496-8; http://link.springer.com/10.1007/s11901-019-00496-8; http://link.springer.com/content/pdf/10.1007/s11901-019-00496-8.pdf; http://link.springer.com/article/10.1007/s11901-019-00496-8/fulltext.html; https://dx.doi.org/10.1007/s11901-019-00496-8; https://link.springer.com/article/10.1007/s11901-019-00496-8
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know